ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Charlotte, North Carolina, United States and 43 other locations

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Huntersville, North Carolina, United States and 137 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Charlotte, North Carolina, United States and 122 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Charlotte, North Carolina, United States and 23 other locations

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50%

in this form. The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The ...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Charlotte, North Carolina, United States and 54 other locations

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non...

Active, not recruiting
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drug: Erlotinib 150/100 mg
Drug: Placebo Erlotinib 150/100mg

Phase 3

AstraZeneca
AstraZeneca

Salisbury, North Carolina, United States and 168 other locations

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benef...

Active, not recruiting
Non-small Cell Lung Cancer
Advanced Solid Tumors
Drug: Carboplatin
Biological: BMS-986442

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Huntersville, North Carolina, United States and 33 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. ...

Enrolling
Lung Cancer, Non-squamous, Non-small Cell
Drug: carboplatin
Drug: pemetrexed

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Rock Hill, South Carolina, United States and 33 other locations

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

(SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Docetaxel
Biological: Sacituzumab Govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Charlotte, North Carolina, United States and 226 other locations

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell...

Enrolling
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Drug: Budigalimab
Drug: ABBV-514

Phase 1

AbbVie
AbbVie

Huntersville, North Carolina, United States and 22 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems